| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5541206 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2013
(10 years ago) | |
| US5948436 | ABBVIE | Pharmaceutical composition |
Sep, 2013
(10 years ago) | |
| US5886036 | ABBVIE | Retroviral protease inhibiting compounds |
Nov, 2013
(10 years ago) | |
| US5484801 | ABBVIE | Pharmaceutical composition for inhibiting HIV protease |
Jan, 2014
(10 years ago) | |
|
US5541206 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2014
(10 years ago) | |
|
US5948436 (Pediatric) | ABBVIE | Pharmaceutical composition |
Mar, 2014
(10 years ago) | |
|
US5886036 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
May, 2014
(9 years ago) | |
| US5648497 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2014
(9 years ago) | |
|
US5484801 (Pediatric) | ABBVIE | Pharmaceutical composition for inhibiting HIV protease |
Jul, 2014
(9 years ago) | |
|
US5648497 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2015
(9 years ago) | |
| US5914332 | ABBVIE | Retroviral protease inhibiting compounds |
Dec, 2015
(8 years ago) | |
| US6284767 | ABBVIE | Retroviral protease inhibiting compounds |
Feb, 2016
(8 years ago) | |
|
US5914332 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jun, 2016
(7 years ago) | |
| US6037157 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
| US6703403 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
|
US6284767 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Aug, 2016
(7 years ago) | |
|
US6703403 (Pediatric) | ABBVIE | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
|
US6037157 (Pediatric) | ABBVIE | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
| US6458818 | ABBVIE | Pharmaceutical composition |
Nov, 2017
(6 years ago) | |
| US6232333 | ABBVIE | Pharmaceutical composition |
Nov, 2017
(6 years ago) | |
| US6521651 | ABBVIE | Pharmaceutical composition |
Nov, 2017
(6 years ago) | |
|
US6521651 (Pediatric) | ABBVIE | Pharmaceutical composition |
May, 2018
(5 years ago) | |
|
US6232333 (Pediatric) | ABBVIE | Pharmaceutical composition |
May, 2018
(5 years ago) | |
|
US6458818 (Pediatric) | ABBVIE | Pharmaceutical composition |
May, 2018
(5 years ago) | |
| US7148359 | ABBVIE | Polymorph of a pharmaceutical |
Jul, 2019
(4 years ago) | |
|
US7148359 (Pediatric) | ABBVIE | Polymorph of a pharmaceutical |
Jan, 2020
(4 years ago) | |
| US7432294 | ABBVIE | Pharmaceutical formulations |
May, 2020
(3 years ago) | |
| US7141593 | ABBVIE | Pharmaceutical formulations |
May, 2020
(3 years ago) | |
| US7364752 | ABBVIE | Solid dispersion pharamaceutical formulations |
Nov, 2020
(3 years ago) | |
|
US7141593 (Pediatric) | ABBVIE | Pharmaceutical formulations |
Nov, 2020
(3 years ago) | |
|
US7432294 (Pediatric) | ABBVIE | Pharmaceutical formulations |
Nov, 2020
(3 years ago) | |
|
US7364752 (Pediatric) | ABBVIE | Solid dispersion pharamaceutical formulations |
May, 2021
(2 years ago) | |
| US6911214 | ABBVIE | Flavoring systems for pharmaceutical compositions and methods of making such compositions |
Nov, 2021
(2 years ago) | |
| US8501219 | ABBVIE | Flavoring systems for pharmaceutical compositions and methods of making such compositions |
Nov, 2021
(2 years ago) | |
|
US6911214 (Pediatric) | ABBVIE | Flavoring systems for pharmaceutical compositions and methods of making such compositions |
May, 2022
(1 year, 11 months ago) | |
| US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
| US8691878 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
| US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
| US8309613 | ABBVIE | Solid pharmaceutical dosage form |
Dec, 2024
(7 months from now) | |
|
US8399015 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
|
US8691878 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
|
US8268349 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
|
US8309613 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Jun, 2025
(1 year, 1 month from now) | |
| US8470347 | ABBVIE | Self-emulsifying active substance formulation and use of this formulation |
Sep, 2026
(2 years from now) | |
|
US8470347 (Pediatric) | ABBVIE | Self-emulsifying active substance formulation and use of this formulation |
Mar, 2027
(2 years from now) | |
| US8377952 | ABBVIE | Solid pharmaceutical dosage formulation |
Oct, 2027
(3 years from now) | |
| US8025899 | ABBVIE | Solid pharmaceutical dosage form |
Dec, 2027
(3 years from now) | |
|
US8377952 (Pediatric) | ABBVIE | Solid pharmaceutical dosage formulation |
Apr, 2028
(3 years from now) | |
|
US8025899 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Jun, 2028
(4 years from now) | |
Kaletra is owned by Abbvie.
Kaletra contains Lopinavir; Ritonavir.
Kaletra has a total of 49 drug patents out of which 35 drug patents have expired.
Expired drug patents of Kaletra are:
- US5541206
- US5948436
- US5886036
- US5484801
- US5541206*PED
- US5948436*PED
- US5886036*PED
- US5648497
- US5484801*PED
- US5648497*PED
- US5914332
- US6284767
- US5914332*PED
- US6037157
- US6703403
- US6284767*PED
- US6703403*PED
- US6037157*PED
- US6458818
- US6232333
- US6521651
- US6521651*PED
- US6232333*PED
- US6458818*PED
- US7148359
- US7148359*PED
- US7432294
- US7141593
- US7364752
- US7141593*PED
- US7432294*PED
- US7364752*PED
- US6911214
- US8501219
- US6911214*PED
Kaletra was authorised for market use on 15 September, 2000.
Kaletra is available in tablet;oral, solution;oral, capsule;oral dosage forms.
Kaletra can be used as treatment of hiv-infection in combination with other antiretroviral agents, administration without food for treatment of hiv-1 infection, treatment of hiv-1 infection in combination with other antiretroviral agents, inhibiting protease with lopinavir and inhibiting an hiv infection with lopinavir, treatment of hiv infection in combination with other antiretroviral agents.
The generics of Kaletra are possible to be released after 14 June, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-124) | Apr 27, 2013 |
Drugs and Companies using LOPINAVIR; RITONAVIR ingredient
Market Authorisation Date: 15 September, 2000
Treatment: Treatment of hiv-infection in combination with other antiretroviral agents; Treatment of hiv infection in combination with other antiretroviral agents; Inhibiting protease with lopinavir and inhibitin...
Dosage: SOLUTION;ORAL; TABLET;ORAL; CAPSULE;ORAL
KALETRA family patents
